Viewing nowLuluca Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Joongheon Pharm Co., Ltd.

MFDS item code 201802678 · Approved 2018.06.27 · Insurance code 053300340
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medicine is used in adults for the treatment of peripheral and central neuropathic pain. It also assists in the management of partial seizures in patients with epilepsy, alleviating symptoms. It helps improve pain and discomfort by treating fibromyalgia. Overall, this medication is used for the relief of various neuropathic pains and seizure symptoms.
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single doseb TID=total daily dose administered in 3 divided doses BID=total daily dose administered in 2 divided doses QD=administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: A supplemental dose refers to an additional dose administered once. No dose adjustment is necessary in patients with hepatic impairment. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so patients should be carefully monitored for depression, mood changes, and unusual behaviors during treatment. Patients with allergies to any components of this medication or certain genetic lactose intolerance disorders should not take this medication. Diabetic patients should be cautious of weight gain and changes in blood sugar levels, and may need adjustments to their blood sugar control medications. If hypersensitivity reactions such as angioedema occur, stop taking the medication immediately and consult a healthcare professional. Older adults may experience symptoms such as dizziness, drowsiness, and loss of consciousness, so special caution is advised at the start of treatment. Some patients may experience blurred vision or changes in vision; if symptoms persist, consult a doctor. When discontinuing this medication, withdrawal symptoms such as insomnia, headaches, and anxiety may occur, so abrupt cessation should be avoided. Patients with a history of drug abuse should be evaluated carefully for the potential misuse and dependence on this medication. Patients with impaired renal function may require dose adjustments. Patients with heart disease should be cautious about symptoms of heart failure when taking this medication. The risk of drowsiness or respiratory depression may be increased when taken with other central nervous system depressants or alcohol, so caution is advised. Pregnant women should avoid taking this medication, especially in the early stages of pregnancy, due to the risk of fetal malformation, and women of childbearing age should use effective contraception. Lactating women should consider stopping breastfeeding or discontinuing the medication, as it may transfer into breast milk and affect the infant. Be cautious of the risk of accidents due to dizziness or drowsiness when driving or operating machinery after taking this medication. In cases of overdose, confusion, drowsiness, depression, seizures, etc., may occur, and immediate medical attention should be sought. This medication should be kept out of reach of children and should not be transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is advisable to maintain storage temperatures between 15 and 30 degrees Celsius.
A hard capsule with a brown-red upper part and a white lower part, containing a white to light yellow powder.
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Joongheon Pharm Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.